2 Risk of MVF was also increased, but this did not reach statistical significance (HR 3.52, 95% CI 0.98-12.64). 2 However, whether the risk of rebound fractures extends to patients with skeletal metastases where denosumab is prescribed at higher doses has not been defined as evidence is currently limited to case reports. 18 , 19 Given the association between denosumab discontinu
1
—
—